Stockreport

C4 Therapeutics Announces First Patient Dosed In Phase 1/2 Clinical Trial Evaluating CFT8634, An Orally Bioavailable BiDAC™ Degrader For The Treatment Of Synovial Sarcoma And SMARCB1-null ...

C4 Therapeutics, Inc.  (CCCC) 
NASDAQ:AMEX Investor Relations: ir.chinacache.com
PDF WATERTOWN, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted [Read more]